LYRA - Lyra Therapeutics Inc Stock Price, Fair Value and News

$0.18-0.02 (-10.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

LYRA Price Action

Last 7 days

-10%

Last 30 days

-25%

Last 90 days

-41.9%

Trailing 12 Months

-94.2%

LYRA RSI Chart

LYRA Valuation

Market Cap

11.8M

Price/Earnings (Trailing)

-0.12

Price/Sales (Trailing)

8.01

EV/EBITDA

0.12

Price/Free Cashflow

-0.15

LYRA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LYRA Fundamentals

LYRA Revenue

Revenue (TTM)

1.5M

Rev. Growth (Yr)

-64.15%

Rev. Growth (Qtr)

-67.39%

LYRA Earnings

Earnings (TTM)

-97.6M

Earnings Growth (Yr)

24.14%

Earnings Growth (Qtr)

75.33%

LYRA Profitability

EBT Margin

-6632.36%

Return on Equity

-473.41%

Return on Assets

-123.94%

Free Cashflow Yield

-686.62%

LYRA Investor Care

Shares Dilution (1Y)

24.53%

Diluted EPS (TTM)

-1.47

LYRA Alerts

Point72 Asset Management, L.P. reported owning 0% of LYRA [2024-11-14]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.7M	1.8M	1.5M	0
2023	1.3M	1.2M	1.4M	1.6M
2022	554.5K	824.0K	1.1M	1.4M
2021	0	0	0	285.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Lyra Therapeutics Inc

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Maria Palasis Ph.D.
WEBSITE	https://lyratherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	73

Lyra Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Lyra Therapeutics Inc? What does LYRA stand for in stocks?

LYRA is the stock ticker symbol of Lyra Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lyra Therapeutics Inc (LYRA)?

As of Wed Nov 20 2024, market cap of Lyra Therapeutics Inc is 11.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LYRA stock?

You can check LYRA's fair value in chart for subscribers.

Is Lyra Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether LYRA is over valued or under valued. Whether Lyra Therapeutics Inc is cheap or expensive depends on the assumptions which impact Lyra Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LYRA.

What is Lyra Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, LYRA's PE ratio (Price to Earnings) is -0.12 and Price to Sales (PS) ratio is 8.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LYRA PE ratio will change depending on the future growth rate expectations of investors.